NCT07403812

Assessing DCog Short for Neurotoxicity in CAR-T

Assessing the Performance of "DCog Short", an iPad-Based Tool for Neurotoxicity Evaluation in CAR-T Cell Therapy Patients: A Pilot Study

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Beth Israel Deaconess Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participants undergoing CAR-T cell therapy.

Detailed description

The goal of this pilot study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participants undergoing CAR-T cell therapy. This is the first time investigators are examining this tool. The U.S. Food and Drug Administration (FDA) has not approved DCOG Short as a mobile application tool to evaluate neurotoxicity for hematologic malignancies. The research study procedures include screening for eligibility, questionnaires, and cognitive assessments. It is expected that about 40 people will take part in this research study.

Conditions

• Neurotoxicity
• Neurotoxicity Syndromes
• Hematologic Malignancy
• Immune Effector Cell Associated Neurotoxicity Syndrome

Interventions

Type	Name	Description
BEHAVIORAL	DCog Short	An iPad-based cognitive assessment instrument to evaluate neurotoxicity and consisting of a series of tests that measure various aspects of cognitive function. After hospital discharge, participants will be provided with iPads which will be returned at the 90 day follow up visit.

Timeline

• Start date: 2026-07-01
• Primary completion: 2026-08-31
• Completion: 2027-08-31
• First posted: 2026-02-11
• Last updated: 2026-02-11

Locations

1 site across 1 country: United States